My Image

FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC™)


Talk to us at 14th Annual Drug Discovery Chemistry meeting in San Diego, Booth 213

On April 9 SARomics Biostructures CEO Björn Walse will also give a presentation with a title:

High-Throughput fragment screening by weak affinity chromatography (WAC)

Björn Walse

WAC™ facts
• Screening and binding assay in one experiment
• Measure fragment affinity to immobilized protein
• Built-in quality control (MS)

WAC™ key advantages
• Robust and accurate (validated against NMR and X-ray)
• Quick set-up and workflow (3 weeks turnaround)
• High throughput (2000-3000 cmpds/week)
• Low material consumption (<5 mg protein)
• Output – High quality data for MedChem (hits with
Kd values)

WAC™ applications
• Screen for novel chemical starting points
• Assess druggability of new targets
• Find differentiated backups in mature projects
• Rescue mode for challenging targets (PPI etc.)


Below is a summary of possible project options (click to see details):

WAC™ pilot
• Screen up to 50 fragments/compounds
• Client supply fragments and/or reference compounds
• Fixed price and fast turnaround

Description
• Limited screen of small library < 50 fragments
• Client supply protein
• Preparation of column with immobilized protein
• Screening in duplicates
• Useful as feasibility step for large WAC™ screen

Deliverables
• List of hits sorted after Δt
ret
• Short report with technical details



MEET WITH US AT BOOTH #213
You are also welcome to schedule a meeting using the form below